title: Acquisition of eyeblink conditioning is critically dependent on normal function in cerebellar cortical lobule HVI.
abstract: Classical conditioning of the nictitating membrane response (NMR)/eyeblink response of rabbits is a simple form of cerebellar-dependent, associative motor learning. Reversible inactivations of the cerebellar nuclei and inferior olive have implicated the olivo-cortico-nuclear loop in the acquisition of nictitating membrane conditioning, but the role of the cerebellar cortex in acquisition has not been tested directly. Here we have used local infusions of the water-soluble, disodium salt of 6-cyano-7-nitroquinoxaline-2,3-dione reversibly to block cerebellar cortical AMPA/kainate receptors in lobule HVI during acquisition training. After the drug effects dissipated, there was no evidence that acquisition had taken place; the subjects behaved as if naive. Further training without inactivation then allowed normal acquisition, and further inactivations during performance of conditioned responses abolished these established responses. There was a strong correlation between the inactivation effects on acquisition and subsequent inactivation effects on performance, indicating that the same eyeblink-control cortical microzones are engaged in learning and expressing this behavior. The cortical component of the olivo-cortico-nuclear loop is essential for acquisition of classically conditioned nictitating membrane response learning, and eyeblink control areas in HVI are critical. Our findings are consistent with models of cerebellar learning that assign essential plasticity to the cortex or to a distribution between levels in olivo-cortico-nuclear modules.
authors.affiliation: Department of Anatomy and Developmental Biology, University College London, London WC1E 6BT, United Kingdom.
authors.forename: P J
authors.initials: PJ
authors.lastname: Attwell
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: C H
authors.initials: CH
authors.lastname: Yeo
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000008:administration & dosage / Q000493:pharmacokinetics; D000161:Acoustic Stimulation; D000818:Animals; D001245:Association Learning / Q000187:drug effects / Q000502:physiology; D001345:Autoradiography; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D002404:Catheterization; D002531:Cerebellum / Q000187:drug effects / Q000502:physiology*; D003215:Conditioning, Eyelid / Q000187:drug effects / Q000502:physiology*; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008845:Microinjections; D011817:Rabbits; D011930:Reaction Time / Q000187:drug effects; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D014316:Tritium
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; D014316:Tritium; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione